Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

373 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.
Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Brouse G, Chan J, Mehmi I, Khalil M, Duvivier HL, Gaba A, Leuva H, Thota R, Yost KJ, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Srkalovic G, et al. Among authors: schilsky rl. JCO Precis Oncol. 2024 Jun;8:e2400026. doi: 10.1200/PO.24.00026. JCO Precis Oncol. 2024. PMID: 38865672 Clinical Trial.
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.
Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL; Cancer and Leukemia Group B. Rini BI, et al. Among authors: schilsky rl. Clin Cancer Res. 2004 Apr 15;10(8):2584-6. doi: 10.1158/1078-0432.ccr-03-0605. Clin Cancer Res. 2004. PMID: 15102658 Clinical Trial.
Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, Stella PJ, Voest E, Yost KJ, Perlmutter J, Pinto N, Kim ES, Schilsky RL. Mangat PK, et al. Among authors: schilsky rl. JCO Precis Oncol. 2018;2018:10.1200/PO.18.00122. doi: 10.1200/PO.18.00122. Epub 2018 Jul 11. JCO Precis Oncol. 2018. PMID: 30603737 Free PMC article.
Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Al Baghdadi T, Garrett-Mayer E, Halabi S, Mangat PK, Rich P, Ahn ER, Chai S, Rygiel AL, Osayameh O, Antonelli KR, Islam S, Bruinooge SS, Schilsky RL. Al Baghdadi T, et al. Among authors: schilsky rl. Target Oncol. 2020 Dec;15(6):743-750. doi: 10.1007/s11523-020-00752-8. Target Oncol. 2020. PMID: 33068284
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Fisher JG, Tait D, Garrett-Mayer E, Halabi S, Mangat PK, Schink JC, Alvarez RH, Veljovich D, Cannon TL, Crilley PA, Pollock T, Calfa CJ, Al Baghdadi T, Thota R, Fleming N, Cotta JA, Rygiel AL, Warren SL, Schilsky RL. Fisher JG, et al. Among authors: schilsky rl. Target Oncol. 2020 Dec;15(6):733-741. doi: 10.1007/s11523-020-00753-7. Target Oncol. 2020. PMID: 33090333
Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations.
Harvey RD, Bruinooge SS, Chen L, Garrett-Mayer E, Rhodes W, Stepanski E, Uldrick TS, Ison G, Khozin S, Rubinstein WS, Schenkel C, Miller RS, Komatsoulis GA, Schilsky RL, Kim ES. Harvey RD, et al. Among authors: schilsky rl. Clin Cancer Res. 2021 May 1;27(9):2430-2434. doi: 10.1158/1078-0432.CCR-20-3857. Epub 2021 Feb 9. Clin Cancer Res. 2021. PMID: 33563634
373 results